Literature DB >> 2880948

The psychological and physiological effects of MDMA on normal volunteers.

J Downing.   

Abstract

The experimental subjects were older than the average general population, more educated and considerably experienced in drug use. They considered themselves to have benefited by their MDMA experience, with no evidence of harm. There were moderate, consistent biochemical, cardiovascular and neurobehavioral changes within normal limits that peaked between one and two hours following ingestion, returning to predrug levels within 24 hours. This experimental situation produced no observed or reported psychological or physiological damage, either during the 24-hour study period or during the three-month follow-up period. While the subjects are not typical of the general population, the findings support the general impression among knowledgeable professionals that MDMA is reasonably safe, produces positive mood changes in users, does not cause negative problems (if used sparingly and episodically) and is without evidence of abuse. Certainly, any drug that causes ataxia, elevates blood pressure and pulse is potentially unsafe. One can say little about safety when effects and side effects are studied for only 24 hours and then a blood cytology is obtained after three months. In this study, safety must exclude long-term toxicity. Not enough is known about MDMA's long-range effects other than information from random anecdotal evidence supplied by a few clinicians plus self-reports by unselected and unsupervised users. From the information presented here, one can only say that MDMA, at the doses tested, has remarkably consistent and predictable psychological effects that are transient and free of clinically apparent major toxicity. The experimental subjects believed that MDMA is both safe and beneficial, but there is insufficient evidence to accurately judge either the drug's potential harm or benefit.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2880948     DOI: 10.1080/02791072.1986.10472366

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  27 in total

1.  [Synthetic drugs: from use to multiple consumption. Some associated risks and a proposal for therapeutic intervention].

Authors:  J Royo-Isach; M Magrané; F Blancafort; J Ferrer
Journal:  Aten Primaria       Date:  2004-03-15       Impact factor: 1.137

2.  Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy").

Authors:  J Sharkey; D E McBean; P A Kelly
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Fatal poisoning by MDMA (ecstasy) and MDEA: a case report.

Authors:  V Fineschi; A Masti
Journal:  Int J Legal Med       Date:  1996       Impact factor: 2.686

Review 4.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

Review 5.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits.

Authors:  N P Pedersen; W W Blessing
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

7.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

8.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

9.  3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.

Authors:  Rebecca L Hartman; Nathalie A Desrosiers; Allan J Barnes; Keming Yun; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-11-15       Impact factor: 4.142

10.  Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  J Clin Psychopharmacol       Date:  2008-08       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.